On the one hand, due to the high expression of ACE2 in alveolar cells and can protect lung function, long-term use of RAAS inhibitors in patients with cardiovascular disease may lead to ACE2 activity increased, which is beneficial to patients with COVID-19. The gene discussed is ACE2; the disease is cardiovascular disorder.